ELT Boston, Platform Technology & Science, GlaxoSmithKline , Waltham, Massachusetts 02451, United States.
J Med Chem. 2014 Feb 27;57(4):1276-88. doi: 10.1021/jm401326j. Epub 2014 Feb 5.
Tuberculosis (TB) is one of the world's oldest and deadliest diseases, killing a person every 20 s. InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis, is the target of the frontline antitubercular drug isoniazid (INH). Compounds that directly target InhA and do not require activation by mycobacterial catalase peroxidase KatG are promising candidates for treating infections caused by INH resistant strains. The application of the encoded library technology (ELT) to the discovery of direct InhA inhibitors yielded compound 7 endowed with good enzymatic potency but with low antitubercular potency. This work reports the hit identification, the selected strategy for potency optimization, the structure-activity relationships of a hundred analogues synthesized, and the results of the in vivo efficacy studies performed with the lead compound 65.
结核病(TB)是世界上最古老、最致命的疾病之一,每 20 秒就有一人因此死亡。分枝杆菌中的烯酰基载体蛋白还原酶(InhA)是一线抗结核药物异烟肼(INH)的作用靶点。直接靶向 InhA 且无需分枝杆菌过氧化氢酶过氧化物酶 KatG 激活的化合物是治疗 INH 耐药菌株感染的有前途的候选药物。将编码文库技术(ELT)应用于直接抑制 InhA 的抑制剂的发现中,得到了具有良好酶活性但抗结核活性低的化合物 7。本工作报道了命中鉴定、效力优化的选择策略、合成的一百个类似物的构效关系以及先导化合物 65 的体内疗效研究结果。